DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer

Oncogene

Volumn 30, Issue 6, 2011, Pages 668-678

  Moncho Amor, V ^a   De Cáceres, I Ibañez ^b   Bandres, E ^c   Martinez Poveda B ^a   Orgaz, J L ^a   Sanchez Perez I ^a   Zazo, S ^d   Rovira, A ^e   Albanell, J ^e   Jimenez B ^a   Rojo, F ^d,e   Belda Iniesta, C ^b   Garcia Foncillas J ^c   Perona, R ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d Cardiac Electrophysiology Unit   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

angiogenesis; DUSP1 MKP1; DUSP6 MKP3; metastasis; non small cell lung cancer; VEGFC

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PROTEIN TYROSINE KINASE; SOMATOMEDIN C;

ANGIOGENESIS; ARTICLE; CANCER INVASION; CELL INTERACTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR CELL;

MUS MUSCULUS;

EID: 79951508418     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.449     Document Type: Article

References (36)

1. Carmeliet P. (2005). Angiogenesis in life, disease and medicine. Nature 438: 932-936. (Pubitemid 43093958)
2. Chang L, Karin M. (2001). Mammalian MAP kinase signalling cascades. Nature 410: 37-40. (Pubitemid 32225829)
3. Chattopadhyay S, Machado-Pinilla R, Manguan-Garcia C, Belda-Iniesta C, Moratilla C, Cejas P et al. (2006). MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 25: 3335-3345. (Pubitemid 43846318)
4. Davis RJ. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
5. Denkert C, Schmitt WD, Berger S, Reles A, Pest S, Siegert A et al. (2002). Expression of mitogen-activated protein kinase phospha-tase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 102: 507-513. (Pubitemid 35316006)
6. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
7. Downward J. (2008). Targeting RAS and PI3K in lung cancer. Nat Med 14: 1315-1316.
8. Ekerot M, Stavridis MP, Delavaine L, Mitchell MP, Staples C, Owens DM et al. (2008). Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem J 412: 287-298. (Pubitemid 351758234)
9. Espina C, Cespedes MV, Garcia-Cabezas MA, Gomez del Pulgar MT, Boluda A, Oroz LG et al. (2008). A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells. Am J Pathol 172: 156-166. (Pubitemid 351186377)
10. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T et al. (2002). Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94: 819-825. (Pubitemid 34705053)
11. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S et al. (2005). Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65: 4739-4746. (Pubitemid 40740810)
12. Hynes NE, MacDonald G. (2009). ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184.
13. Johnson GL, Lapadat R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912. (Pubitemid 35425238)
14. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549. (Pubitemid 36808649)
15. Keyse SM. (2000). Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol. 12: 186-192. (Pubitemid 30142565)
16. Keyse SM. (2008). Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27: 253-261.
17. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J. (2003). The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24: 1445-1454. (Pubitemid 37160834)
18. Ling L, Kung HJ. (1995). Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol Cell Biol 15: 6582-6592.
19. Linger RM, Keating AK, Earp HS, Graham DK. (2008). TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100: 35-83. (Pubitemid 351932179)
20. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W et al. (1996). Expression of mitogen-activated protein kinase phospha-tase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 149: 1553-1564. (Pubitemid 26363962)
21. Lu X, Yan CH, Yuan M, Wei Y, Hu G, Kang Y. (2010). In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res 70: 3905-3914.
22. Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA et al. (2009). AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res 15: 1277-1287.
23. Morrison DJ, Kim MK, Berkofsky-Fessler W, Licht JD. (2008). WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression. Mol Cancer Res 6: 1225-1231.
24. Nutt JE, Foster PA, Mellon JK, Lunec J. (2007). hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours. Br J Cancer 96: 762-768. (Pubitemid 46376625)
25. Offersen BV, Pfeiffer P, Andreasen P, Overgaard J. (2007). Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 56: 43-50. (Pubitemid 46356642)
26. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K et al. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183. (Pubitemid 32458157)
27. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I et al. (2005). Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 11: 7344-7353. (Pubitemid 41507693)
28. Rojo F, Gonzalez-Navarrete I, Bragado R, Dalmases A, Menendez S, Cortes-Sempere M et al. (2009). Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin Cancer Res 15: 3530-3539.
29. Sanchez-Perez I, Martinez-Gomariz M, Williams D, Keyse SM, Perona R. (2000). CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin Oncogene. Oncogene 19: 5142-5152.
30. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS et al. (2006). Multiple oncogenic changes (K-RAS (V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 66: 2116-2128.
31. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T et al. (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69: 3256-3261.
32. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M et al. (2007). p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 39: 750-758. (Pubitemid 46848588)
33. Wada T, Penninger JM. (2004). Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849. (Pubitemid 38638846)
34. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M et al. (2007). Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 67: 2517-2525. (Pubitemid 46548936)
35. Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B et al. (2009). Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol 50: 948-957.
36. Zhang SC, Hironaka S, Ohtsu A, Yoshida S, Hasebe T, Fukayama M et al. (2006). Computer-assisted analysis of biopsy specimen microvessels predicts the outcome of esophageal cancers treated with chemoradiotherapy. Clin Cancer Res 12: 1735-1742.